Exelixis | EXEL - Pre Tax Profit


Exelixis reported $267.69M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bayer EUR -3.37B 2.21B Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY -7.94B 29.94B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Exelixis USD 267.69M 15M Mar/2026
Genmab DKK 55M 427M Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Moderna USD -799M 612M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Sanofi EUR -1.16B 6.23B Dec/2025
Takeda JPY -52.48B 186.34B Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026